Abarceo Pharma, a pre-clinical stage company, is developing a platform for the treatment of mitochondrial diseases, with an initial focus on Type 2 Diabetes (T2D).
Ascelia is an oncology-dedicated drug development company focused on the development of novel drugs to improve the life expectancy and quality of life for people living with cancer.
Research in the area of diabetes pharmaceuticals.
CLEERPLUS® is the latest good idea from Sweden. It is a topical treatment for a wide array of ailments.
We are providing innovative staining solutions for biomedical research. Our customers are research labs, clinical institutions and universities around the world.
Galenica works with the formulation, production and quality control of pharmaceuticals and drug-related products. They also develop their own medicines.
At Infingent Innovations, we understand that nanotechnology is the future and its applications are endless. We use our expertise to create products which are at the forefront of a technological revolution.
Food Security is a global, expensive issue, concerning both consumers and the industry.
We offer raw materials and extracts from plants produced in a controlled, clean room laboratory environment.
Christina Junvik, M.SC. has almost 20 years of experience in pharmaceutical drug development and provides services to pharma and biotech companies. Main therapeutic area is oncology, early translational phase with clinical focus.
A translational research programme covering five research groups at Malmö University.
Start-up pharma company PILA PHARMA AB (PILA) addresses the issue of the global diabetes pandemia by developing an oral drug for treatment of newly diagnosed type 2 diabetic patients.
We believe that reliable regulatory expertise is the key to successful market access for your pharma project.
MEDEON IS AN IMPORTANT LIFE SCIENCE NODE WITH ITS CENTRAL LOCATION AND SPECIFIC NETWORKS, OFFERING ONE OF THE ÖRESUND REGION'S BEST GROWTH ENVIRONMENTS FOR COMPANIES. MEDEON PROMOTES INTERCHANGE BETWEEN THE ACADEMIC WORLD, PUBLIC SECTOR AND INDUSTRY.
Catrine Pauckstadt
Communications Manager